Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$657K Buy
2,613
+174
+7% +$37.4K 0.34% 57
2026
Q1
$531K Sell
2,439
-19
-0.8% -$4.21K 0.33% 58
2025
Q4
$562K Buy
2,458
+18
+0.7% +$4.1K 0.34% 54
2025
Q3
$565K Buy
2,440
+115
+5% +$23.4K 0.35% 54
2025
Q2
$431K Buy
2,325
+33
+1% +$6.13K 0.3% 67
2025
Q1
$480K Sell
2,292
-45
-2% -$8.75K 0.38% 56
2024
Q4
$415K Buy
2,337
+7
+0.3% +$1.29K 0.3% 73
2024
Q3
$460K Sell
2,330
-183
-7% -$34.2K 0.34% 70
2024
Q2
$431K Buy
2,513
+91
+4% +$15.1K 0.35% 66
2024
Q1
$441K Buy
2,422
+125
+5% +$21.5K 0.4% 57
2023
Q4
$356K Buy
+2,297
New +$335K 0.42% 54

Other funds holding ABBV

M3 Advisory Group's ABBV Position: Q2 2026 in Review

M3 Advisory Group increased its AbbVie (ABBV) stake by 7.1% in Q2 2026, buying an estimated $37.4K and bringing the position to 2,613 shares worth $657K. The position accounts for 0.34% of the portfolio, ranked #57.

M3 Advisory Group first reported a position in ABBV in Q4 2023 and has held it in 11 quarters since. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • M3 Advisory Group held 2,613 shares of AbbVie worth $657K as of Q2 2026.
  • M3 Advisory Group bought 174 AbbVie shares in Q2 2026, an estimated $37.4K.
  • AbbVie made up 0.34% of M3 Advisory Group's portfolio in Q2 2026, its #57 holding.
  • M3 Advisory Group first reported a position in AbbVie in Q4 2023 and has held it in 11 quarters since.
  • 4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on M3 Advisory Group's 13F filing for Q2 2026, filed 24 Jul 2026.